SEC Form 4 · accession 0001209191-16-120031
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul B Cleveland
Officer — Chief Executive Officer · Director
Period of report
May 11, 2016
Accepted (ET)
May 13, 2016 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.14 | May 11, 2016 | A | 381,000 | A | — | May 10, 2026 | Common Stock | 381,000 | 381,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary of May 11, 2016 (the "Vesting Commencement Date"), and then 1/48th of the shares subject to the option vest and become exercisable monthly thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.